These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 3431518)

  • 61. Hemodynamic effects of isosorbide-5-mononitrate in acute and chronic treatment of coronary heart disease.
    Schuster P; Trieb G; Wiechmann HW
    Z Kardiol; 1983; 72 Suppl 3():251-4. PubMed ID: 6666229
    [TBL] [Abstract][Full Text] [Related]  

  • 62. [Administration of various dosages of retard isosorbide-5-mononitrate in patients with stable angina pectoris on combined therapy].
    Chernova EV; Kuchinskaia NG; Barysheva OV; Bezborodova IuV; Shatukhina EIu; Aleshin OI
    Klin Med (Mosk); 2002; 80(1):55-7. PubMed ID: 11855323
    [TBL] [Abstract][Full Text] [Related]  

  • 63. [New drug forms of isosorbide dinitrate: the problem of an objective evaluation in patients with ischemic heart disease].
    Martsevich SIu; Metelitsa VI; Kozyreva MP; Blagodatskikh SV; Simkhaev LS; Piotrovskiĭ VK
    Farmakol Toksikol; 1991; 54(3):53-6. PubMed ID: 1915825
    [TBL] [Abstract][Full Text] [Related]  

  • 64. [Iso Mack Retard 40 mg. Coronary drug for long term therapy and prophylaxis in coronary circulation disorders (angina pectoris)].
    Wien Klin Wochenschr; 1980 Oct; 92(19):695-6. PubMed ID: 7467343
    [No Abstract]   [Full Text] [Related]  

  • 65. [The effect of IS-5-MN in coronary disease. Monocentric double-blind crossover comparison with ISDN retard and placebo].
    Müller G; Schmidt-Voigt J
    Med Welt; 1981 Apr; 32(14A):554-6. PubMed ID: 7242319
    [No Abstract]   [Full Text] [Related]  

  • 66. [Tolerance for the antianginal effect of nitrates. Approaches to its study].
    Martsevich SIu; Shakarova SSh; Metelitsa VI; Strel'tsov AA; Vygodin VA
    Ter Arkh; 1984; 56(9):46-50. PubMed ID: 6515547
    [TBL] [Abstract][Full Text] [Related]  

  • 67. [Effect of 50 mg isosorbide-5-nitrate retard on the stress tolerance of patients with coronary heart disease].
    Eggeling T; Jansen W; Osterspey A; Tauchert M; Hilger HH
    Med Klin (Munich); 1986 Apr; 81(8):275-80. PubMed ID: 3785087
    [No Abstract]   [Full Text] [Related]  

  • 68. Nitrate tolerance.
    Parker JO
    Herz; 1984 Jun; 9(3):137-45. PubMed ID: 6430767
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Monitoring medical management of coronary artery disease: patient selection, optimal management, and potential problems for diagnosis.
    Cerqueira MD
    J Nucl Cardiol; 2000; 7(4):392-4. PubMed ID: 10958283
    [No Abstract]   [Full Text] [Related]  

  • 70. [How is antianginal therapy with pentaerythritol tetranitrate executed?].
    Schneider CA
    Dtsch Med Wochenschr; 2002 Nov; 127(46):2465. PubMed ID: 12432490
    [No Abstract]   [Full Text] [Related]  

  • 71. [Comparison of the effectiveness of olicard 40 retard and cardonit 40 prolongatum preparations in treatment of stable coronary heart disease].
    Kurpesa M; Krzemińska-Pakuła M; Kedzia E; Trzos E; Musiał W; Peruga Z
    Wiad Lek; 1994 Aug; 47(15-16):587-90. PubMed ID: 7716955
    [TBL] [Abstract][Full Text] [Related]  

  • 72. [Isosorbide-5-mononitrate. A metabolite of isosorbide dinitrate].
    Aldershvile J; Abildgaard U
    Ugeskr Laeger; 1985 Jun; 147(24):1948-9. PubMed ID: 4024344
    [No Abstract]   [Full Text] [Related]  

  • 73. Isosorbide-5-mononitrate in angina pectoris.
    Poss M; Racicot D; Kiser WR
    Ann Intern Med; 1994 Oct; 121(7):547. PubMed ID: 8093205
    [No Abstract]   [Full Text] [Related]  

  • 74. [Slow-release nitrates: a critical review].
    Ambrosioni E; Strocchi E
    Cardiologia; 1987 Nov; 32(11):1283-6. PubMed ID: 3129193
    [No Abstract]   [Full Text] [Related]  

  • 75. Acute and chronic use of isosorbide 5-mononitrate in patients with heart failure.
    Stephens JD; Marks C; Woodings D; Vandenburg MJ
    Cardiology; 1987; 74 Suppl 1():69-71. PubMed ID: 3607807
    [No Abstract]   [Full Text] [Related]  

  • 76. Acute effect of various doses of isosorbide-5-mononitrate on hemodynamic and exercise performance in coronary artery disease.
    Jansen W; Meyer L; Tauchert M
    Am J Cardiol; 1988 Mar; 61(9):31E-35E. PubMed ID: 3348138
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Effect of lisinopril and isosorbide-5-mononitrate on hemodynamics and mortality in rats with permanent coronary artery occlusion.
    Riva E; Kurosaki M; Latini R
    J Cardiovasc Pharmacol; 1992 Sep; 20(3):490-5. PubMed ID: 1279297
    [TBL] [Abstract][Full Text] [Related]  

  • 78. [Therapeutic experiences with viskenit (LBI-45) in ischemic heart disease and symptoms of angina pectoris].
    Ripka O; Chvatíková J
    Med Monatsschr; 1977 Jun; 31(6):281-3. PubMed ID: 20565
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Effectiveness of modified release isosorbide mononitrate affected by incorrect use.
    Hider JD; Shehab Z; Courteney-Harris R
    BMJ; 2000 Feb; 320(7233):483. PubMed ID: 10678861
    [No Abstract]   [Full Text] [Related]  

  • 80. [Delayed release forms of nitrates--are they obsolete today?].
    Rietbrock N
    Dtsch Med Wochenschr; 1985 Jan; 110(3):110-2. PubMed ID: 3967587
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.